Mohammed Harris, PhD, MBA, MPH, MPA is an executive leader working at the intersection of diagnostics innovation, translational science, multiomics, and preventive health. Dr. Harris serves on the Executive Board of TimepointDx and Board of Directors for multiple non-profits organizations (Global Newborn Solutions, TUBB2A Foundation, Myositis Support and Understanding Association). He is an investor/advisor to multiple healthcare technology startups, including Biostate AI, K-Dense, Ecosense.io, and LoBio Sciences. His career spans pharma, clinical research, public health and policy, and clinical diagnostics, giving him an integrated perspective on how biomarkers, real-world evidence, and patient-centered technologies can reshape healthcare delivery. He has led cross-functional programs in diagnostic development, biomarker strategy, observational research, registries, clinical operations, and RWE/RWD/HEOR, with a particular focus on expanding precision and preventive health beyond traditional care settings.

Dr. Harris is a pioneer in longitudinal capillary multiomics and accessible, low-burden sampling strategies designed to support early detection, biomarker discovery, decentralized clinical research, and scalable population screening. He has held senior leadership roles across organizations including Alexion, Eurofins Scientific, Johnson and Johnson, Amgen, and Bristol Myers Squibb, and serves in board and advisory roles supporting rare disease, newborn health, and patient advocacy initiatives. His work is especially focused on building practical partnerships across industry, academia, government, and nonprofit organizations to advance health equity and bring patient-centric innovation to underserved, rural, and rare disease communities. Dr. Harris is an early career investigator with a technology focus on combinatorial multiomics libraries that capture genomics, transcriptomics, and proteomics on a single patterned flow cell.